2017

Peer Reviewed Publications in Print or Other Media

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Cin PD, Pak C, Alyea EP, Budde E, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2017 Nov 28. pii: S1083-8791(17)30870-4.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res. 2017 Nov 1;77(21):e62-e66.

A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas

Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau CA, Kluk MJ, Christie AL, Lee WY, Tarjan DR, Guo B, Donohue LKH, Gillespie SM, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi RB, Bernstein BE, Aster JC, Pear WS. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017 Oct 17;21(3):784-797.

Inhibition of USP10 induces degradation of oncogenic FLT3

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec;13(12):1207-1215.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 6;8(32):52026-52044.

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma

Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017 Sep 28;130(13):1491-1498

Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA

Day TA, Layer JV, Cleary JP, Guha S, Stevenson KE, Tivey T, Kim S, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM. Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 Jun 13;8:15918.

Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas

Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY*, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weinstock DM, Faryabi RB, Lim MS, Elenitoba-Johnson KSJ. Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas. Proceedings of the National Academy of Sciences 2017;114:6581-6.

PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. 

Day TA*, Layer JV*, Cleary JP*, Guha S*, Stevenson KE, Tivey T*, Kim S*, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM.  PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nature Communications 2017;8:15110

Deletion of ribosomal protein genes is a common vulnerability in human cancer, particularly in concert with TP53 mutation

Ajore R, Raiser D, McConkey M, Joud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B. Deletion of ribosomal protein genes is a common vulnerability in human cancer, particularly in concert with TP53 mutation.  EMBO Mol Med 2017;9:498-507

Anti-leukemic Activity of the TYK2 selective inhibitor NDI-031301 in T-cell Acute Lymphoblastic Leukemia

Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwoods JR, Tiv H, Sanda T, Weinstock DM, Look AT.  Anti-leukemic Activity of the TYK2 selective inhibitor NDI-031301 in T-cell Acute Lymphoblastic Leukemia.  Brit J Haematology 2017;177:271-82

Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia

Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee AS, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia.  Clin Cancer Res 2017;23(4):1012-24

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen r, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA*, LaCasce A, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddizi T, Sohani AR, Zain J, Rosen ST, Kwak L W, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.  J Clin Onc 2017;35(1):24-31

Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias

Dunford A^, Weinstock DM^, Savova V, Schumacher SE, Cleary JP*, Yoda A*, Sullivan TJ, Gimelbrant AA, Beroukhim R, Lawrence MS^, Getz G^, Lane AA^*. Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias. ^equal contribution Nature Genetics 2017;49:10-16

Other Peer-Reviewed Publications

Meehan TF, Conte N, Goldstein TC, Inghirami G, Murakami MA*, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush M, Byrne AT, Caldas C, Christie AL, Clark D, Dowst H, Dry JR, Doroshow J, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt DM, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KK, Mason JC, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.  Cancer Research [in press].

Giwa S, Lewis J, Langer R, Church GM, Sachs D, Markmann J, Boyden E, Lee A, Alvarez L, Elliott G, Weinstock DM, Acker J, Pomahac B, Uygun MK, Eidbo E, Schmalz B, Tocchio A, Weegman B, Fahy G, Rubinsky B, Bischof J, Elliott J, Brandacher G, Storey K, Nelson D, Woodruff T, Demirci U, Brockbank K, Woods E, Ben R, Baust JG, Gao D, Fuller B, Rabin Y, Kravitz D, Taylor MJ, Toner M.  The Promise of Organ and Tissue Preservation to Transform Medicine.  Nature Biotechnology 2017;35:530-42

10.1038/nbt.3889

Reviews, Chapters, Monographs and Editorials

Murakami M, Weinstock DM. The next best thing. Nature 2017

http://rdcu.be/vqkH

Yoshida N, Weinstock DM.  It takes a village to unmask HSTL. Cancer Disc 2017;7:352-3

10.1158/2159-8290.CD-17-0160